Figures computed from official regulatory filings — .
Analysttarget 74.2 USD (+147%) · consensus 4.67/5 · 13 buy · 2 hold · 0 sell
Ownershipinsiders 1.01% · institutions 118.1% · short 27.2% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vera Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
48 buys184 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Fordyce Marshall | Sell | $684.5K | SEC |
| Fordyce Marshall | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | Exercise | $53.6K | SEC |
| Young Joseph R | Exercise | $19.7K | SEC |
| Young Joseph R | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | Exercise | $53.6K | SEC |
| Fordyce Marshall | Sell | $649.6K | SEC |
| Fordyce Marshall | Sell | $3.4K | SEC |
| Fordyce Marshall | Exercise | $134K | Unusual size | SEC |
| Fordyce Marshall | Sell | $40.8K | SEC |
| Fordyce Marshall | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | Sell | $158.8K | SEC |
| Fordyce Marshall | Exercise | $53.6K | SEC |
| Fordyce Marshall | Sell | $95.9K | SEC |
| Fordyce Marshall | Exercise | $53.6K | SEC |
| Fordyce Marshall | Sell | $1.4M | Unusual size | SEC |
| Fordyce Marshall | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | Sell | $698.4K | Unusual size | SEC |
| Fordyce Marshall | Sell | $450K | SEC |
| Fordyce Marshall | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fordyce Marshall | Sell | $521K | SEC |
| Boman Nancy Lee | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boman Nancy Lee | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SEIDENBERG BETH Ctrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |